CRNXCongressional Stock Trades
Crinetics Pharmaceuticals, Inc.
Pharmaceutical Preparations
Congressional stock trades in Crinetics Pharmaceuticals, Inc. (CRNX) from House and Senate STOCK Act filings. See which members of Congress bought or sold, disclosed amounts, and filing dates.
Total Trades
4
Politicians Trading
2
Last Traded
Jul 30, 2026
Trading History
| Politician | Notified | Traded | Type | Amount | Change |
|---|---|---|---|---|---|
| Gilbert Ray Cisneros, Jr.D | Sep 4, 2026 | Jul 30, 2026 | Sell | $15,001 - $50,000 | - |
| Josh GottheimerD | Apr 10, 2025 | Mar 19, 2025 | Sell | $1,001 - $15,000 | +145.02% |
Price History
About Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.